Glaukos

Glaukos is an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. Founded in 1998, the company first developed Micro-Invasive Glaucoma Surgery (MIGS) as an alternative to the traditional glaucoma treatment paradigm and launched its first MIGS device commercially in 2012. It completed an initial public offering in June 2015, and its shares are traded on the New York Stock Exchange.

Glaukos was founded in 1998. In 1999 the first trabecular micro-bypass glaucoma stent was developed, and in 2001 the first human implant of a micro-bypass glaucoma stent was performed. In 2005 a landmark trial evaluating iStent in conjunction with cataract surgery began. Glaukos received a Category III CPT code in 2008 to describe insertion of a flow device into the trabecular meshwork of the eye. In 2012 Glaukos established a direct sales organization and launched iStent in the United States. In 2013 Glaukos secured 100% Medicare coverage for the iStent procedure. In 2014 Glaukos established a direct sales organization and launched iStent inject in Germany. Glaukos completed an initial public offering in 2015. In 2016 iStent was approved in Japan and launched in Australia and Canada. In 2017 Glaukos expanded into 17 countries with direct sales operations. In 2018 iStent inject was approved by the FDA in combination with cataract surgery, with a US commercial launch. In 2019 Glaukos acquired Avedro, establishing the cornerstone of a new corneal health franchise; acquired DOSE Medical, establishing a new R&D retinal program; and entered a licensing agreement with Intratus for a non-invasive, cream-based drug delivery platform. In 2021 Glaukos completed patient enrollment in a Phase 3 clinical program for iDose TR, surpassed 200 peer-reviewed publications on iStent technologies, and entered a licensing agreement with Attillaps Holdings, Inc. In 2023 Glaukos received FDA Approval for iDose TR (travoprost intracameral implant), 75 mcg, and commenced first-in-human clinical development for its retina program (GLK-401). In 2026 Glaukos exceeded 3 million iStent devices implanted.

• 2021

  Ivantis and Glaukos settle patent litigation

  Ivantis announced that it had entered into an agreement with Glaukos to settle and dismiss all pending global litigation between them. The terms include payments by Ivantis, royalties on specified Hydrus Microstent sales, and a limited cross-license and covenant not to sue.

  Source

Read more

• 2021.09.15

  Reported2021.09.15

  Ivantis and Glaukos settle patent litigation[4]Ivantis and Glaukos settle patent litigationprnewswire.com

  Ivantis announced that it had entered into an agreement with Glaukos to settle and dismiss all pending global litigation between them. The terms include payments by Ivantis, royalties on specified Hydrus Microstent sales, and a limited cross-license and covenant not to sue.

Read more

1. 1Advancing the Treatment of Ophthalmic Diseases | Glaukosglaukos.com
2. 2Our History | About Us | Glaukosglaukos.com
3. 3About Us | Glaukosglaukos.com
4. 4Ivantis and Glaukos settle patent litigationprnewswire.com